Author:
Cheng Kun,Zhang Jing,Ye Lu-Ya,Lin Mou-Hui,Ding Xiao-Yan,Zheng Xiao-E,Zhou Xiao-Fen
Funder
Natural Science Foundation of Fujian Province
Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. Sudhakaran S, Bottiglieri T, Tecson KM, Kluger AY, McCullough PA. Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions. Rev Cardiovasc Med. 2018;19(3):77–88.
2. Su X, Peng D. New insight into sortilin in controlling lipid metabolism and the risk of atherogenesis. Biol Rev Camb Philos Soc. 2020;95(1):232–43.
3. Siddiqui AA. Metabolic syndrome and its association with colorectal cancer: a review. Am J Med Sci. 2011;341(3):227–31.
4. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009;5(12):713–21.
5. Centers for Disease C, Prevention. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol–United States, 1999–2002 and 2005–200. MMWR Morb Mortal Wkly Rep. 2011;60(4):109–14.